Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 454-380-1 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- repeated dose toxicity: oral
- Adequacy of study:
- other information
Data source
Reference
- Reference Type:
- other: Body responsible for the test
- Title:
- Unnamed
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: 96/54/EG, B.7; OECD 407 (1995)
- GLP compliance:
- yes
- Limit test:
- no
Test animals
- Species:
- other: rat, Wistar Hsd Cpb:WU
Administration / exposure
- Route of administration:
- oral: unspecified
- Vehicle:
- other: 2 % cremophor in water
- Details on oral exposure:
- Method of administration:
Gavage - Duration of treatment / exposure:
- Test duration: 28 days
- Frequency of treatment:
- Dosing regime: 7 days/week
- No. of animals per sex per dose:
- Male: 5 animals at 0 mg/kg bw/day
Male: 5 animals at 20 mg/kg bw/day
Male: 5 animals at 100 mg/kg bw/day
Male: 5 animals at 500 mg/kg bw/day
Female: 5 animals at 0 mg/kg bw/day
Female: 5 animals at 20 mg/kg bw/day
Female: 5 animals at 100 mg/kg bw/day
Female: 5 animals at 500 mg/kg bw/day
Results and discussion
Results of examinations
- Details on results:
- Clinical observations:
There were no test substance related deaths. One male
treated at 500 mg/kg bw/d died shortly after blood sampling
(for laboratory study) on day 28 of the study without
clinical signs prior to death. The cause of death was
considered to be due to the blood sampling procedure.
Treatment with 500 mg/kg bw/d resulted in clinical findings
in male rats. There were piloerection (3/5), decreased
motility (2/5), closed eyes (1/5), discolored feces (1/5).
In male rats partly statistically significant decrease in
body weights was noted at 500 mg/kg bw/d (-10 % at the end
of the study).
There were no test substance-related effects during
functional observational battery including functional
observations, open field observations, reflex testing and
grip strength measurements.
Laboratory findings:
Hematology revealed statistically significant decreased
counts of erythrocytes, leukocytes, and basophils; and
atypical cells in males at 500 mg/kg bw/d. A trend to lower
leukocyte and lymphocyte counts was observed also in female
rats at >= 100 mg/kg bw/d.
Clinical biochemistry revealed statistically significant
(but not dose-related) increase of aspartate
aminotransferase in females at 20 and 100 mg/kg bw/d; and
decreased concentrations in creatinine and protein in males
and females at 500 mg/kg bw/d, and additional in albumin in
females, respectively.
No effects on the activity of enzymes and on the content of
cytochrome P-450 in liver tissue samples were detected.
Effects in organs:
The absolute and relative weights of testes were
statistically significant decreased at 100 mg/kg bw/d
(-13 %) and 500 mg/kg bw/d (-60 %).
At necropsy treatment-related changes were recorded from the
male sex organs. The testes were diminished in size, and
discolored at >= 100 mg/kg bw/d, and epididymides, prostate,
and seminal vesicle were diminished in size at 500 mg/kg
bw/d.
At microscopy treatment-related changes were seen in several
organs: spleen, Payer's patches, testes, epididymides,
prosta/seminal vesicles, ovaries and thyroid gland. In the
spleen a dose-related increased atrophy (lymphocytic
depletion) of the marginal zone of the white pulp was
observed in rats of either sex at >= 100 mg/kg bw/d, and an
increased extramedullary hematopoiesis in male rats given
500 mg/kg bw/d. Minimal lymphoid depletion of the Payer's
patches was present in 4/5 males and 3/5 females treated at
500 mg/kg bw/d.
Corresponding to the macroscopic findings in male sexual
organs minimal to marked degeneration of the testicular
epithelium was observed in males treated at >= 100 mg/kg
bw/d. Minor changes such as vacuolation of the germinal
epithelium were observed at 100 mg/kg bw/d. The testicular
changes were accompanied by aspermia, oligospermia and an
increase of spermatic debris in the epididymides at
>= 100 mg/kg bw/d. One male treated at 500 mg/kg bw/d had an
atrophy of the prostate and the seminal vesicles. In the
ovaries central necrosis of the corpora lutea was observed
in 1/5 females at 100 mg/kg bw/d and in 3/5 females at
500 mg/kg bw/d. An effect on the estrous cycle was not
visible. A stimulation of the follicular cells of the
thyroid gland (follicular cell hypertrophy of minimal
severity score) was observed in higher frequency in males at
500 mg/kg bw/d.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 20 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
- Dose descriptor:
- NOEL
- Effect level:
- 20 mg/kg bw/day (nominal)
- Basis for effect level:
- other: original NCD unit is mg/kg/day.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- Classified as: Xn - harmful
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.